CN1246116A - 磺胺类衍生物、它们的制备方法以及它们作为药物的用途 - Google Patents

磺胺类衍生物、它们的制备方法以及它们作为药物的用途 Download PDF

Info

Publication number
CN1246116A
CN1246116A CN97181816A CN97181816A CN1246116A CN 1246116 A CN1246116 A CN 1246116A CN 97181816 A CN97181816 A CN 97181816A CN 97181816 A CN97181816 A CN 97181816A CN 1246116 A CN1246116 A CN 1246116A
Authority
CN
China
Prior art keywords
phenyl
methoxy
methylpiperazin
chloro
benzenesulfonamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN97181816A
Other languages
English (en)
Chinese (zh)
Inventor
S·M·布罗米格
F·D·金
P·A·维曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9626377.7A external-priority patent/GB9626377D0/en
Priority claimed from GBGB9700901.3A external-priority patent/GB9700901D0/en
Priority claimed from GBGB9722757.3A external-priority patent/GB9722757D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of CN1246116A publication Critical patent/CN1246116A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C07D261/16—Benzene-sulfonamido isoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
CN97181816A 1996-12-19 1997-12-15 磺胺类衍生物、它们的制备方法以及它们作为药物的用途 Pending CN1246116A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9626377.7A GB9626377D0 (en) 1996-12-19 1996-12-19 Novel compounds
GBGB9700901.3A GB9700901D0 (en) 1997-01-17 1997-01-17 Novel compounds
GB9626377.7 1997-10-27
GBGB9722757.3A GB9722757D0 (en) 1997-10-27 1997-10-27 Novel compounds
GB9722757.3 1997-10-27
GB9700901.3 1997-10-27

Publications (1)

Publication Number Publication Date
CN1246116A true CN1246116A (zh) 2000-03-01

Family

ID=27268644

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97181816A Pending CN1246116A (zh) 1996-12-19 1997-12-15 磺胺类衍生物、它们的制备方法以及它们作为药物的用途

Country Status (31)

Country Link
US (2) US6423717B1 (https=)
EP (1) EP0946539B1 (https=)
JP (1) JP2001506646A (https=)
KR (1) KR20000069554A (https=)
CN (1) CN1246116A (https=)
AP (1) AP1277A (https=)
AR (1) AR010795A1 (https=)
AT (1) ATE247099T1 (https=)
AU (1) AU729056B2 (https=)
BG (1) BG103530A (https=)
BR (1) BR9713734A (https=)
CA (1) CA2275492A1 (https=)
CZ (1) CZ220399A3 (https=)
DE (1) DE69724142T2 (https=)
DZ (1) DZ2376A1 (https=)
EA (1) EA002351B1 (https=)
ES (1) ES2203831T3 (https=)
HU (1) HUP0000658A3 (https=)
ID (1) ID22821A (https=)
IL (1) IL130297A0 (https=)
MA (1) MA24426A1 (https=)
NO (1) NO993003L (https=)
NZ (1) NZ335970A (https=)
OA (1) OA11066A (https=)
PE (1) PE46899A1 (https=)
PL (1) PL334337A1 (https=)
SK (1) SK80899A3 (https=)
TR (1) TR199901361T2 (https=)
TW (1) TW418205B (https=)
UY (1) UY24819A1 (https=)
WO (1) WO1998027081A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100455570C (zh) * 2003-03-11 2009-01-28 弗·哈夫曼-拉罗切有限公司 喹啉酮/苯并嗪酮衍生物及其用途
CN102159564A (zh) * 2008-09-17 2011-08-17 苏文生命科学有限公司 芳基磺酰胺胺化合物及它们作为5-ht6配体的用途
CN102459199A (zh) * 2009-04-30 2012-05-16 雅培股份有限两合公司 适于治疗响应于5-羟色胺5-ht6受体调节的病症的苯磺酰苯胺化合物
CN102459200A (zh) * 2009-04-30 2012-05-16 雅培股份有限两合公司 适用于治疗响应于调节血清素5-ht6受体的疾病的苯磺酰基苯胺化合物
CN101039904B (zh) * 2004-10-14 2014-09-24 Abbvie德国有限责任两合公司 适于治疗对于多巴胺d3受体调节有反应的病症的杂环化合物
CN105367472A (zh) * 2014-08-12 2016-03-02 广东东阳光药业有限公司 吲哚啉类衍生物及其在药物上的应用
CN105367473A (zh) * 2014-08-12 2016-03-02 广东东阳光药业有限公司 吲哚啉类衍生物及其在药物上的应用

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
AU736256B2 (en) * 1997-07-11 2001-07-26 Smithkline Beecham Plc Novel compounds
CA2318731C (en) 1998-01-29 2012-05-29 Tularik Inc. Ppar-gamma modulators
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
GB9810671D0 (en) * 1998-05-18 1998-07-15 Pfizer Ltd Anti-pruritic agents
GB9818914D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9818916D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9820113D0 (en) 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
GB9926302D0 (en) * 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
WO2001045694A1 (en) * 1999-12-21 2001-06-28 Smithkline Beecham Corporation Urotensin-ii receptor antagonists
SE9904723D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US6818639B2 (en) 2000-07-21 2004-11-16 Biovitrum Ab Pharmaceutical combination formulation and method of treatment with the combination
SE0002754D0 (sv) * 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
SE0002739D0 (sv) * 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New use
US6399617B1 (en) 2000-07-21 2002-06-04 Biovitrum Ab Use
AU2001288053A1 (en) * 2000-09-18 2002-03-26 Toa Eiyo Ltd. N-substituted benzothiophenesulfonamide derivatives
US7071220B2 (en) 2000-09-18 2006-07-04 Toa Eiyo Ltd. N-substituted benzothiophenesulfonamide derivatives
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
EP1341783A1 (en) 2000-11-21 2003-09-10 Smithkline Beecham Plc Isoquinoline derivatives useful in the treatment of cns disorders
KR20030064852A (ko) 2000-12-22 2003-08-02 이시하라 산교 가부시끼가이샤 아닐린 유도체 또는 그의 염 및 이들을 함유하는사이토카인 생산 억제제
WO2002088101A2 (en) * 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Inhibitors of bace
EP1385495A4 (en) * 2001-05-07 2005-12-21 Smithkline Beecham Corp SULPHONAMIDES
JP2004529168A (ja) * 2001-05-07 2004-09-24 スミスクライン・ビーチャム・コーポレイション スルホンアミド
US6743796B2 (en) * 2001-05-07 2004-06-01 Wyeth Piperazinyl-isatins
AR033879A1 (es) * 2001-05-07 2004-01-07 Smithkline Beecham Corp Compuesto sulfonamida, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para la obtencion de dicho compuesto
JP2004535390A (ja) * 2001-05-07 2004-11-25 スミスクライン・ビーチャム・コーポレイション スルホンアミド
WO2002089793A1 (en) * 2001-05-07 2002-11-14 Smithkline Beecham Corporation Sulfonamides
GB0111186D0 (en) * 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
US7718650B2 (en) 2001-05-11 2010-05-18 Biovitrum Ab Aryl sulfonamide compounds for treating obesity
RS88803A (sr) * 2001-05-11 2007-02-05 Biovitrum Ab., Nova jedinjenja arilsulfonamida za lečenje gojaznosti, dijabetesa tipa ii i poremećaja cns
WO2002092585A1 (en) 2001-05-11 2002-11-21 Biovitrum Ab Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
EP1401813B1 (en) 2001-06-07 2007-02-07 F. Hoffman-la Roche AG New indole derivatives with 5-ht6 receptor affinity
IL158590A0 (en) 2001-06-11 2004-05-12 Biovitrum Ab Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
DE60212841T2 (de) 2001-06-15 2007-06-21 F. Hoffmann-La Roche Ag 4 piperazinylindolderivate mit affinität zum 5-ht6-rezeptor
US6727264B1 (en) * 2001-07-05 2004-04-27 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as MCH selective antagonists
WO2003013510A1 (en) * 2001-08-07 2003-02-20 Smithkline Beecham P.L.C. 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
HRP20040090A2 (en) * 2001-08-10 2004-12-31 Hoffmann La Roche Arylsulfonyl derivatives with 5-ht<sub>6</sub> receptor affinity
JP4221294B2 (ja) 2001-09-05 2009-02-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 摂食亢進剤および食欲不振症治療剤
SE0103644D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic isoquinoline compounds
EP1450806B1 (en) * 2001-11-09 2009-04-29 Biovitrum AB (publ) Use of sulfonamide derivatives in the treatment of obesity or for the reduction of food intake
RS44304A (sr) 2001-11-22 2007-06-04 Biovitrum Ab., Inhibitori 11-beta- hidroksistereoidne dehidrogenaze tipa 1
RS44204A (sr) 2001-11-22 2007-06-04 Biovitrum Ab., Inhibitori 11-beta- hidroksistereoidne dehidrogenaze tipa 1
CN1321115C (zh) * 2001-11-30 2007-06-13 霍夫曼-拉罗奇有限公司 作为哮喘治疗中的ccr－3受体拮抗剂的哌嗪衍生物
WO2003066056A1 (en) * 2002-02-05 2003-08-14 Glaxo Group Limited Method of promoting neuronal growth
AU2003203148A1 (en) * 2002-02-05 2003-09-02 High Point Pharmaceuticals, Llc Novel aryl- and heteroarylpiperazines
KR20040081201A (ko) * 2002-02-13 2004-09-20 글락소 그룹 리미티드 항정신병제로서 벤젠술폰아미드 유도체
US20050085461A1 (en) * 2002-02-13 2005-04-21 Cooper David G. Benzenesulfonamide derivatives
WO2003068751A1 (en) * 2002-02-13 2003-08-21 Glaxo Group Limited 7-arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5-ht6 receptor affinity for the reatment of cns disorders
BRPI0308696B8 (pt) 2002-03-27 2021-05-25 Axovant Sciences Gmbh composto derivado de quinolina, seu processo de preparação, sua composição farmacêutica e seus usos
US20040142948A1 (en) * 2002-05-07 2004-07-22 Dashyant Dhanak Sulfonamides
HRP20041030B1 (hr) * 2002-05-13 2013-03-31 F. Hoffmann - La Roche Ag Derivati benzoksazina kao regulatori 5-ht6 i njihova upotreba
EP1513828A1 (en) * 2002-06-20 2005-03-16 Biovitrum AB New compounds useful for the treatment of obesity, type ii diabetes and cns disorders
JP4754821B2 (ja) * 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
EP1897881A3 (en) 2002-06-20 2009-03-18 Biovitrum AB (publ) Compounds useful for the treatment of obesity, type II diabetes and CNS disorders
PL376479A1 (en) 2002-10-18 2005-12-27 F.Hoffmann-La Roche Ag 4-piperazinyl benzenesulfonyl indoles with 5-ht6 receptor affinity
AU2003295408A1 (en) * 2002-11-06 2004-06-03 Smithkline Beecham Corporation Sulfonamides
AU2003291262A1 (en) * 2002-11-06 2004-06-03 Smithkline Beecham Corporation Sulfonamides
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
US7153858B2 (en) 2003-01-31 2006-12-26 Epix Delaware, Inc. Arylpiperazinyl compounds
US20060257613A1 (en) * 2003-02-13 2006-11-16 Horst Berneth Metal complexes as light-absorbing compounds in the information layer of optical data carriers
US7319111B2 (en) * 2003-02-20 2008-01-15 Encysive Pharmaceuticals, Inc. Phenylenediamine Urotensin-II receptor antagonists and CCR-9 antagonists
WO2004087654A2 (en) * 2003-03-31 2004-10-14 Janssen Pharmaceutica N.V. Phospholipase c inhibitors for use in treating inflammatory disorders
US6946466B2 (en) * 2003-04-10 2005-09-20 Schering Ag Aromatic sulfonamides as peroxynitrite-rearrangement catalysts
US20040204422A1 (en) * 2003-04-14 2004-10-14 Abbott Gmbh & Co. Kg. N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
PT1558582E (pt) 2003-07-22 2006-05-31 Arena Pharm Inc Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo
GB0320320D0 (en) * 2003-08-29 2003-10-01 Glaxo Group Ltd Novel compounds
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
BRPI0417833A (pt) * 2003-12-19 2007-04-17 Biovitrum Ab novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6
SE0303480D0 (sv) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
US7381728B2 (en) * 2004-07-28 2008-06-03 Glaxo Group Limited Piperazine derivatives useful for the treatment of gastrointestinal disorders
CN102114244A (zh) * 2004-09-30 2011-07-06 弗·哈夫曼-拉罗切有限公司 治疗认知障碍的组合物和方法
ATE520659T1 (de) 2004-10-14 2011-09-15 Abbott Gmbh & Co Kg Zur behandlung von auf die modulation des dopamin-d3-rezeptors ansprechenden erkrankungen geeignete azabicycloheptylverbindungen
WO2006062481A1 (en) * 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
EP1676841A1 (en) * 2004-12-30 2006-07-05 Esteve Laboratorios Dr. Esteve S.A. Substitited indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their prepartion and use in medicaments
KR100931928B1 (ko) * 2005-01-12 2009-12-15 인제대학교 산학협력단 P25/cdk5 저해 화합물을 포함하는 퇴행성 뇌질환의 예방 및치료용 약학 조성물
RU2499795C2 (ru) 2005-07-04 2013-11-27 Хай Пойнт Фармасьютикалс, ЛЛС Антагонисты гистаминовых н3-рецепторов
EA013875B1 (ru) 2005-08-12 2010-08-30 Сувен Лайф Сайенсиз Лимитед Аминоарильные сульфонамидные производные как функциональные 5-нтлиганды
WO2007020654A1 (en) 2005-08-16 2007-02-22 Suven Life Sciences An improved process for the preparation of losartan
WO2007076875A2 (en) * 2006-01-06 2007-07-12 Aarhus Universitet Compounds acting on the serotonin transporter
TW200808709A (en) 2006-03-31 2008-02-16 Glaxo Group Ltd Novel compounds
TW200808762A (en) 2006-04-19 2008-02-16 Abbott Gmbh & Co Kg Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor
CA2648891A1 (en) * 2006-04-19 2007-10-25 Abbott Gmbh & Co. Kg Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor
US8318927B2 (en) 2006-05-23 2012-11-27 High Point Pharmaceuticals, Llc 6-(4-cyclopropylpiperazin-1-yl)-2′-methyl-[3, 4′]-bipyridine and its uses as a medicament
SG163547A1 (en) 2006-05-29 2010-08-30 High Point Pharmaceuticals Llc 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
JP2010508300A (ja) * 2006-10-26 2010-03-18 フライン、ギャリー・エー． アクアポリン修飾因子並びに浮腫および体液平衡異常の治療のためのそれらの使用方法
AU2007343063B2 (en) 2007-01-08 2011-02-17 Suven Life Sciences Limited 5-(Heterocyclyl)alkyl-N-(arylsulfonyl)indole compounds and their use as 5-HT6 ligands
JP5208963B2 (ja) * 2007-01-10 2013-06-12 エフ．ホフマン−ラ ロシュ アーゲー キマーゼ阻害剤としてのスルホンアミド誘導体
US8507469B2 (en) 2007-03-23 2013-08-13 Abbott Gmbh & Co. Kg Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
BRPI0809873A2 (pt) 2007-05-03 2018-11-13 Suven Life Sciences Ltd "composto, processo para a preparação do composto, método para o tratamento de uma desordem do sistema nervoso central, composição farmacêutica, uso do composto, método para testar antagonistas e antagonistas com seletividade para o receptor 5-th6 e método de tratamento"
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
EP2016943B1 (en) * 2007-07-19 2011-02-23 Laboratorios del Dr. Esteve S.A. Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments
CN101835748B (zh) 2007-10-26 2012-11-14 苏文生命科学有限公司 氨基芳基磺胺化合物及其作为5-ht6配体的用途
PA8802201A1 (es) * 2007-11-02 2009-06-23 Abbott Gmbh & Co Kg Compuestos de bencensulfonalida apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EP2297097A2 (en) * 2008-06-11 2011-03-23 Irm Llc Compounds and compositions useful for the treatment of malaria
WO2010032257A1 (en) 2008-09-17 2010-03-25 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
UA100192C2 (en) 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
KR101073703B1 (ko) 2009-04-07 2011-10-14 한국화학연구원 피페라진 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계 질환의 예방 또는 치료용 약학적 조성물
US8343959B2 (en) 2009-04-30 2013-01-01 Abbott Gmbh & Co. Kg N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
MX2011011520A (es) 2009-04-30 2012-06-19 Abbott Gmbh & Co Kg Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfon amida o bencensulfonil-fenil-(piperazina u homopiperazina) adecuados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6.
CA2786072C (en) 2010-01-05 2014-10-28 Suven Life Sciences Limited Sulfone compounds as 5-ht6 receptor ligands
PH12013500547A1 (en) 2010-09-22 2013-06-10 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012059431A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
WO2012059432A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
ES2413911B1 (es) * 2011-12-15 2014-05-14 Universidad De Zaragoza Agente inhibidor de la agregación del peptido beta amiloide.
CA2866910A1 (en) 2012-03-20 2013-09-26 Adamed Sp. Z O.O. Sulphonamide derivatives of benzylamine for the treatment of cns diseases
MX394360B (es) 2013-03-14 2025-03-24 Sumitomo Pharma Oncology Inc Inhibidores de jak2 y alk2 y metodos para su uso.
DK3027613T3 (en) 2013-07-25 2018-06-25 Univ Jagiellonski Pyrroloquinoline derivatives as 5-HT6 antagonists, preparation and use thereof
WO2015158313A1 (en) 2014-04-19 2015-10-22 Sunshine Lake Pharma Co., Ltd. Sulfonamide derivatives and pharmaceutical applications thereof
MX386419B (es) 2015-01-06 2025-03-18 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
WO2016201373A1 (en) 2015-06-12 2016-12-15 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
EP3939965A1 (en) 2015-06-22 2022-01-19 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
CN108926565A (zh) * 2017-05-26 2018-12-04 中国科学院上海生命科学研究院 五羟色胺受体亚型6小分子激活剂及拮抗剂在防治阿尔茨海默症中的应用
WO2019180176A1 (en) 2018-03-21 2019-09-26 Spherium Biomed, S.L. Composition for the treatment of schizophrenia and/or psychosis
ES2987794T3 (es) 2018-06-06 2024-11-18 Arena Pharm Inc Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
MX2021000977A (es) 2018-07-26 2021-04-12 Sumitomo Pharma Oncology Inc Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE81861C (https=)
NZ193654A (en) * 1979-05-16 1984-08-24 Wuelfing Johann A Naphthalene sulphonamido-alkyl-piperidines,pyrrolidines or piperazines and pharmaceutical compositions
US4315014A (en) * 1980-09-24 1982-02-09 Warner-Lambert Company Antibacterial amide compounds and pharmaceutical composition containing the same
EP0076072B1 (en) * 1981-09-24 1987-05-13 BEECHAM - WUELFING GmbH &amp; Co. KG Sulphonamides
CN85106905A (zh) * 1985-08-08 1987-02-04 Fmc公司 含有1-芳基-δ2-1，2，4，-三唑啉-5-酮类的除草剂及其制备方法
EP0462179A4 (en) * 1989-02-27 1992-03-18 The Du Pont Merck Pharmaceutical Company Novel sulfonamides as radiosensitizers
JPH04330057A (ja) * 1991-05-01 1992-11-18 Hiroyoshi Hidaka アニリンアリールスルホン酸アミド類及び薬剤として許容され得るその酸付加塩
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
DE4206531A1 (de) * 1992-03-02 1993-09-09 Bayer Ag N-aryl-stickstoffheterocyclen
DE4303376A1 (de) * 1993-02-05 1994-08-11 Bayer Ag Substituierte Triazolinone
WO1995006637A1 (en) * 1993-09-03 1995-03-09 Smithkline Beecham Plc Indole and indoline derivatives as 5ht1d receptor antagonists
WO1995011243A1 (en) * 1993-10-19 1995-04-27 Smithkline Beecham Plc Benzanilide derivatives as 5ht-1d receptor antagonists
EP0733048A1 (en) * 1993-12-07 1996-09-25 Smithkline Beecham Plc Heterocyclic biphenylylamides useful as 5ht1d antagonists
JPH10500960A (ja) * 1994-05-28 1998-01-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ１ｄ−アンタゴニスト活性を有するアミド誘導体
US5939451A (en) 1996-06-28 1999-08-17 Hoffmann-La Roche Inc. Use of sulfonamides
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100455570C (zh) * 2003-03-11 2009-01-28 弗·哈夫曼-拉罗切有限公司 喹啉酮/苯并嗪酮衍生物及其用途
CN101039904B (zh) * 2004-10-14 2014-09-24 Abbvie德国有限责任两合公司 适于治疗对于多巴胺d3受体调节有反应的病症的杂环化合物
CN102159564A (zh) * 2008-09-17 2011-08-17 苏文生命科学有限公司 芳基磺酰胺胺化合物及它们作为5-ht6配体的用途
CN102159564B (zh) * 2008-09-17 2014-06-18 苏文生命科学有限公司 芳基磺酰胺胺化合物及它们作为5-ht6配体的用途
CN102459199A (zh) * 2009-04-30 2012-05-16 雅培股份有限两合公司 适于治疗响应于5-羟色胺5-ht6受体调节的病症的苯磺酰苯胺化合物
CN102459200A (zh) * 2009-04-30 2012-05-16 雅培股份有限两合公司 适用于治疗响应于调节血清素5-ht6受体的疾病的苯磺酰基苯胺化合物
CN105367472A (zh) * 2014-08-12 2016-03-02 广东东阳光药业有限公司 吲哚啉类衍生物及其在药物上的应用
CN105367473A (zh) * 2014-08-12 2016-03-02 广东东阳光药业有限公司 吲哚啉类衍生物及其在药物上的应用
CN105367473B (zh) * 2014-08-12 2020-02-11 广东东阳光药业有限公司 吲哚啉类衍生物及其在药物上的应用
CN105367472B (zh) * 2014-08-12 2020-04-21 广东东阳光药业有限公司 吲哚啉类衍生物及其在药物上的应用

Also Published As

Publication number Publication date
CA2275492A1 (en) 1998-06-25
US6599904B2 (en) 2003-07-29
ES2203831T3 (es) 2004-04-16
TW418205B (en) 2001-01-11
DE69724142T2 (de) 2004-06-03
SK80899A3 (en) 2000-02-14
NO993003D0 (no) 1999-06-18
AU729056B2 (en) 2001-01-25
DE69724142D1 (de) 2003-09-18
HUP0000658A2 (hu) 2001-02-28
WO1998027081A1 (en) 1998-06-25
US6423717B1 (en) 2002-07-23
EA199900561A1 (ru) 2000-02-28
IL130297A0 (en) 2000-06-01
NZ335970A (en) 2001-10-26
BG103530A (bg) 2000-01-31
US20030069233A1 (en) 2003-04-10
CZ220399A3 (cs) 1999-11-17
AR010795A1 (es) 2000-07-12
ATE247099T1 (de) 2003-08-15
NO993003L (no) 1999-06-18
ID22821A (id) 1999-12-09
PL334337A1 (en) 2000-02-28
AP1277A (en) 2004-05-05
EP0946539B1 (en) 2003-08-13
DZ2376A1 (fr) 2002-12-28
EA002351B1 (ru) 2002-04-25
PE46899A1 (es) 1999-06-24
KR20000069554A (ko) 2000-11-25
AU6090498A (en) 1998-07-15
OA11066A (en) 2003-03-10
TR199901361T2 (xx) 1999-08-23
HUP0000658A3 (en) 2001-03-28
UY24819A1 (es) 2001-08-27
MA24426A1 (fr) 1998-07-01
AP9901556A0 (en) 1999-06-30
EP0946539A1 (en) 1999-10-06
BR9713734A (pt) 2000-03-28
JP2001506646A (ja) 2001-05-22

Similar Documents

Publication Publication Date Title
CN1246116A (zh) 磺胺类衍生物、它们的制备方法以及它们作为药物的用途
CN1163484C (zh) 4-芳酰基-哌啶-ccr-3受体拮抗剂ⅲ
CN1143852C (zh) 茚并、萘并和苯并芳庚并二氢噻唑衍生物、它们的制备和它们作为减食欲药物的用途
CN1041087C (zh) 芳基乙酰胺及其制备方法和应用
CN1374953A (zh) 含氮的6－员芳香环化合物
CN1247571C (zh) 新颖的2h－哒嗪－3－酮衍生物、含有它们的药物组合物和活性成分的制备方法
CN1076447A (zh) 抗肿瘤组合物及治疗方法
CN1094037A (zh) N-苯甲酰苯胺衍生物
SK10832002A3 (sk) Deriváty 1,3-dihydro-2H-indol-2-ónu, spôsob ich prípravy a farmaceutická kompozícia, ktorá ich obsahuje
CN1087900A (zh) 苯甲酰胍、其制备方法和作为药物及含有它们的药剂的用途
CN1211572A (zh) 趋化细胞因子受体－3拮抗剂
CN1260781A (zh) 具有综合的5ht1a、5ht1b和5ht1d受体拮抗剂活性的吲哚衍生物
EP1335722A2 (en) Compounds useful in the treatment of cns disorders
CN1315950A (zh) 作为5－ht4受体拮抗剂的二氢苯并二噁烯羧酰胺与酮衍生物
CN1350452A (zh) 糖尿病的预防或治疗药
CN86106428A (zh) 抗肿瘤方法及其化合物
CN1039996C (zh) N－取代氮杂双环庚烷衍生物及其用途
CN1326440A (zh) 哌啶ccr－3受体拮抗剂
CN1656069A (zh) 作为5－羟色胺－6配体的1－(氨基烷基)－3－磺酰基吲哚和1－(氨基烷基)－3－磺酰基吲唑衍生物
CN1922162A (zh) 烷基哌嗪－和烷基高哌嗪－羧酸酯衍生物、其制备方法及其作为faah酶抑制剂的用途
CN1301970C (zh) 2,4－取代吲哚和它们作为5－ht6调节剂的用途
CN1863527A (zh) 1－磺酰基吲哚衍生物、其制备及其作为5－ht6配体的用途
CN1993120A (zh) 用于治疗阿尔茨海默氏病的芳基乙酸和相关化合物
CN1325397A (zh) 2－哌嗪烷基氨基苯并吡咯衍生物∶多巴胺受体亚型特异配体
CN1829508A (zh) 吲哚－4磺酰胺衍生物,它们的制备及其作为5－ht－6调节剂的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: MITSUBISHI PHARMACEUTICAL CORP.

Free format text: FORMER OWNER: WEIFU CO., LTD.

Effective date: 20021206

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20021206

Patentee after: MITSUBISHI PHARMA Corp.

Patentee before: WELFIDE Corp.

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication